Thoroughly review all warnings and essential safety information regarding these drugs.See important safety information
Among patients who previously used a GLP-1-based medication, most switched from injectable anti-obesity medications (AOM), including injectable AOM semaglutide (sold as Wegovy) and AOM tirzepatide (sold as Zepbound)
These may include an increase in blood pressure and heart rate, difficulties with sleep such as insomnia, feelings of nervousness and restlessness, and the potential for dependence, abuse, or withdrawal symptoms with prolonged use
Animal models of colitis have demonstrated that GLP-1 receptor activation may reduce intestinal inflammation through multiple mechanisms, including modulation of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-) and interleukin-6 (IL-6), enhancement of intestinal barrier function, and reduction of oxidative stress